Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene

被引：7
|
作者：
Wouters, Yannick [1 ,2 ]
Nevejan, Louis [3 ]
Louwagie, Annelies [2 ]
Devos, Helena [3 ]
Dewaele, Barbara [4 ,5 ]
Selleslag, Dominik [6 ]
Michaux, Lucienne [4 ,5 ]
机构：
[1] Sint Franciscus Hosp, Dept Lab Med, Heusden Zolder, Belgium
[2] Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium
[3] AZ Sint Jan Hosp Brugge Oostende, Dept Lab Med, Brugge, Belgium
[4] Univ Hosp Leuven, Ctr Human Genet, Leuven, Belgium
[5] Katholieke Univ Leuven, Leuven, Belgium
[6] AZ Sint Jan Hosp Brugge Oostende, Dept Hematol, Brugge, Belgium
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 192卷 / 04期
关键词：
PCM1‐ JAK2; ruxolitinib; B‐ ALL; t(8; 9); PCM1; NEOPLASMS; JAK2;
D O I：
10.1111/bjh.17340
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e112 / e115
页数：4
相关论文
共 50 条
  • [31] Identification of STRBP as a Novel JAK2 Fusion Partner Gene in a Young Adult With Philadelphia Chromosome-Like B-Lymphoblastic Leukemia
    Zhang, Xin-Yue
    Dai, Hai-Ping
    Li, Zheng
    Yin, Jia
    Lang, Xing-Ping
    Yang, Chun-Xiao
    Xiao, Sheng
    Zhu, Ming-Qing
    Liu, Dan-Dan
    Liu, Hong
    Shen, Hong-Jie
    Wu, De-Pei
    Tang, Xiao-Wen
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [32] Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) transtocation -: reply
    Tzankov, A
    Heiss, S
    HUMAN PATHOLOGY, 2006, 37 (04) : 500 - 502
  • [33] Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?
    Bain, Barbara J.
    Ahmad, Shahzaib
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (06) : 809 - 817
  • [34] The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and ZBTB20-JAK2 gene fusion presenting as B-lymphoblastic leukemia
    Lee, Winston Y.
    Pfau, Ruthann B.
    Choi, Sarah M.
    Yang, Jiong
    Xiao, Hong
    Putnam, Eileen M.
    Ryan, Russell J. H.
    Bixby, Dale L.
    Shao, Lina
    COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2020, 6 (02):
  • [35] Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma Sharing the PCM1-JAK2 Fusion and a Common T-Cell Clone
    Riedlinger, Gregory M.
    Chojecki, Aleksander
    Aviv, Hana
    Weissmann, David
    Joshi, Sonali
    Murphy, Susan M.
    Hirshfield, Kim M.
    Ganesan, Shridar
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 8
  • [36] Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review
    Sun, Yingxin
    Cai, Yifeng
    Chen, Jia
    Cen, Jiannong
    Zhu, Mingqing
    Pan, Jinlan
    Wu, Depei
    Sun, Aining
    Chen, Suning
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Clinicopathologic Study of Myeloid/Lymphoid Neoplasms with Altered PDGFRA, PGDFRB, FGFR1 and PCM1-JAK2
    Aqil, Barina
    Sukhanova, Madina
    Jennings, Lawrence
    Lu, Xinyan
    Chen, Yi-Hua
    Gao, Juehua
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 804 - 805
  • [38] Clinicopathologic Study of Myeloid/Lymphoid Neoplasms with Altered PDGFRA, PGDFRB, FGFR1 and PCM1-JAK2
    Aqil, Barina
    Sukhanova, Madina
    Jennings, Lawrence
    Lu, Xinyan
    Chen, Yi-Hua
    Gao, Juehua
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 804 - 805
  • [39] Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2
    Pozdnyakova, Olga
    Orazi, Attilio
    Kelemen, Katalin
    King, Rebecca
    Reichard, Kaaren K.
    Craig, Fiona E.
    Quintanilla-Martinez, Leticia
    Rimsza, Lisa
    George, Tracy, I
    Horny, Hans-Peter
    Wang, Sa A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2021, 155 (02) : 160 - 178
  • [40] Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib
    Chen, Xue
    Wang, Fang
    Zhang, Yang
    Ma, Xiaoli
    Liu, Mingyue
    Cao, Panxiang
    Zhou, Lin
    Wang, Lan
    Zhang, Xian
    Wang, Tong
    Liu, Hongxing
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2020, 8 (03):
12345